Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Joel Bard"'
Autor:
Hannah M. Jones, John Tolsma, Zhiwei Zhang, Paul Jasper, Haobin Luo, Gregory L. Weber, Katherine Wright, Joel Bard, Robert Bell, Dean Messing, Kerry Kelleher, Nicole Piche‐Nicholas, Robert Webster
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 9, Pp 534-541 (2020)
Monoclonal antibodies (mAbs) can be engineered to have “extended half‐life” and “catch and release” properties to improve target coverage. We have developed a mAb physiologically‐based pharmacokinetic model that describes intracellular tr
Externí odkaz:
https://doaj.org/article/cc8e779c5f0a47c995659f13bc259620
Autor:
Kenneth G. Geles, Yijie Gao, Andreas Giannakou, Latha Sridharan, Ting-Ting Yamin, Jing Zhang, Riyez Karim, Joel Bard, Nicole Piche-Nicholas, Manoj Charati, Andreas Maderna, Judy Lucas, Jonathon Golas, Magali Guffroy, Steven Pirie-Shepherd, Marc Roy, Jessie Qian, Tania Franks, Wenyan Zhong, Christopher J. O’Donnell, Lioudmila Tchistiakova, Hans-Peter Gerber, Puja Sapra
Publikováno v:
Cell Reports Medicine, Vol 2, Iss 5, Pp 100279- (2021)
Summary: Aberrant NOTCH3 signaling and overexpression is oncogenic, associated with cancer stem cells and drug resistance, yet therapeutic targeting remains elusive. Here, we develop NOTCH3-targeted antibody drug conjugates (NOTCH3-ADCs) by bioconjug
Externí odkaz:
https://doaj.org/article/76d0c5083adc4e25955529b3fcfbbf6d
Autor:
Nicole Piche-Nicholas, Rob Webster, Gregory Weber, John Tolsma, Kerry Kelleher, Haobin Luo, Katherine Wright, Robert D. Bell, Dean Messing, Joel Bard, Hannah M. Jones, Zhiwei Zhang, Paul Jasper
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 9, Pp 534-541 (2020)
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 9, Pp 534-541 (2020)
Monoclonal antibodies (mAbs) can be engineered to have “extended half‐life” and “catch and release” properties to improve target coverage. We have developed a mAb physiologically‐based pharmacokinetic model that describes intracellular tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4957d4dcb466a570f9e2f82e2fe50691
https://pubmed.ncbi.nlm.nih.gov/32697437
https://pubmed.ncbi.nlm.nih.gov/32697437
Autor:
Magali Guffroy, Steven Pirie-Shepherd, Puja Sapra, Judy Lucas, Jonathon Golas, Kenneth G. Geles, Joel Bard, Nicole Piche-Nicholas, Riyez Karim, Hans-Peter Gerber, Latha Sridharan, Lioudmila Tchistiakova, Andreas Giannakou, Jing Zhang, Manoj Charati, Tania Franks, Wenyan Zhong, Ting-Ting Yamin, Yijie Gao, Jessie Qian, Marc D. Roy, Andreas Maderna, Christopher J. O’Donnell
Publikováno v:
Cell Reports Medicine, Vol 2, Iss 5, Pp 100279-(2021)
Cell Reports Medicine
Cell Reports Medicine
Summary Aberrant NOTCH3 signaling and overexpression is oncogenic, associated with cancer stem cells and drug resistance, yet therapeutic targeting remains elusive. Here, we develop NOTCH3-targeted antibody drug conjugates (NOTCH3-ADCs) by bioconjuga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0591a6f1173fde81b769ca95def20526
https://doi.org/10.1016/j.xcrm.2021.100279
https://doi.org/10.1016/j.xcrm.2021.100279
Autor:
William S. Somers, Lydia Mosyak, Orla Cunningham, Chao Tu, Amy Tam, Brian J. Fennell, Joel Bard, Edward R. Lavallie, Mark Stahl, Wayne Stochaj, Laura Lin, William J.J. Finlay, Virginie Terraube
Publikováno v:
Journal of Biological Chemistry. 291:1267-1276
Fully-human single-chain Fv (scFv) proteins are key potential building blocks of bispecific therapeutic antibodies, but they often suffer from manufacturability and clinical development limitations such as instability and aggregation. The causes of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::261c02617c3e30bb3256d94b8c8a3cef
https://doi.org/10.1074/jbc.m115.688010
https://doi.org/10.1074/jbc.m115.688010
Autor:
Renee Ramsey, Sri Laxmanan, Orla Cunningham, Lydia Mosyak, Brian J. Fennell, Joel Bard, Steven P. Braithwaite, Bénédicte Autin, Chao Tu, Christopher John Corcoran, Anne S. Klein, Edward R. Lavallie, Leeying Wu, Wei Cao, Eugenia Kouranova, Heather H. Shih, Anthony J. Milici, William J.J. Finlay, Janet E. Paulsen, Jo Ann Dumin, Deirdre Ní Shúilleabháin, Matthew Allister Lambert, Maya Arai, Mostafa Ait-Zahra, Davinder Gill
Publikováno v:
Journal of Biological Chemistry. 287:44425-44434
Highly specific antibodies to phosphoepitopes are valuable tools to study phosphorylation in disease states, but their discovery is largely empirical, and the molecular mechanisms mediating phosphospecific binding are poorly understood. Here, we repo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e527a805643d52b9e49f16ee3c80cdac
https://doi.org/10.1074/jbc.m112.415935
https://doi.org/10.1074/jbc.m112.415935
Autor:
Hwei-Ru Tsou, George Theodore Grosu, Semiramis Ayral-Kaloustian, Natasja Brooijmans, Joel Bard, Ker Yu, Matthew Gregory Bursavich, Tarek S. Mansour, Gary Harold Birnberg, Irwin Hollander, Lourdes Toral-Barza, Gloria Jean Macewan
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:2321-2325
We discovered 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Since phenolic OH groups pose metabolic liability, one
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::423078d3b728d24b55623b4661e9206d
https://doi.org/10.1016/j.bmcl.2010.01.135
https://doi.org/10.1016/j.bmcl.2010.01.135
Autor:
Darrell Panza, Kristine Svenson, Jason Shaoyun Xiang, Xianbin Tian, Christian E. Johnson, Xin Xu, James Tobin, Xiangping Li, Huan-Qiu Li, Mylene Perreault, Joel Bard, Tarek S. Mansour, Seung Hahm, Eddine Saiah, Ariful Qadri, Vipin Suri, Eva Chenail, Zhao-Kui Wan, Manus Ipek, Yuzhe Xing
Publikováno v:
Journal of Medicinal Chemistry. 52:5449-5461
Cortisol and the glucocorticoid receptor signaling pathway have been implicated in the development of diabetes and obesity. The reduction of cortisone to cortisol is catalyzed by 11beta-hydroxysteroid dehydrogenase type I (11beta-HSD1). 2,4-Disubsitu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42f85d0e0f8af0cfd247553b12a776ed
https://doi.org/10.1021/jm900639u
https://doi.org/10.1021/jm900639u
Autor:
David Malwitz, David J. Richard, Kristine Svenson, Lourdes Toral-Barza, Natasja Brooijmans, Ker Yu, Kevin J. Curran, Jeroen C. Verheijen, Judy Lucas, Arie Zask, Pawel Nowak, Joshua Kaplan, Weiguo Zhang, Robert T. Abraham, Irwin Hollander, Joel Bard, James Joseph Gibbons, Semiramis Ayral-Kaloustian, Tarek S. Mansour
Publikováno v:
Journal of Medicinal Chemistry. 52:5013-5016
The mammalian target of rapamycin (mTOR), a central regulator of growth, survival, and metabolism, is a validated target for cancer therapy. Rapamycin and its analogues, allosteric inhibitors of mTOR, only partially inhibit one mTOR protein complex.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47c29065dfa8ed03476485767435f485
https://doi.org/10.1021/jm900851f
https://doi.org/10.1021/jm900851f
Autor:
Girija Krishnamurthy, Huiming Cheng, Anita Y. M. Howe, S V Johann, Srinivas K. Chunduru, Tarek S. Mansour, John O'Connell, Stanley Mullen, Dorothy C. Young, Joel Bard, Rajiv Chopra
Publikováno v:
Antimicrobial Agents and Chemotherapy. 52:3327-3338
HCV-796 selectively inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. In hepatoma cells containing a genotype 1b HCV replicon, HCV-796 reduced HCV RNA levels by 3 to 4 log 10 HCV copies/μg total RNA (the concentration of the compou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2edb40e0684b7d6742a6ea4d89f1a18c
https://doi.org/10.1128/aac.00238-08
https://doi.org/10.1128/aac.00238-08